Tag: Watchman

BIBA MedTech LAA (quarterly) Monitor

BIBA Briefings: Longest and largest follow-up data for Watchman supports its...

Data from the CAP and CAP2 registries—which contain the longest and largest follow-up of patients—add to previous evidence that left atrial appendage closure (LAAC)...

Boston Scientific initiates trial comparing left atrial appendage closure to direct...

According to a press release, Boston Scientific has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial...

Simultaneous TAVI and left atrial appendage closure is feasible

Thomas S Gilhofer (University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland) and others report in Structural Heart that a combined procedure...

Short-term DAPT is feasible for patients undergoing percutaneous LAA closure

Felix Weise (Cardioangiologisches Centrum Bethanien, Frankfurt, Germany) and others report in EuroIntervention that a strategy of six weeks’ duration of dual antiplatelet therapy (DAPT)...
PREVAIL watchman

Vivek Reddy on the final outcomes of PREVAIL and PROTECT-AF

Boston Scientific has announced the final five-year outcomes data from the PREVAIL study during a late-breaking clinical trial session at this year’s Transcatheter Cardiovascular...
PREVAIL watchman

TCT 2017: Boston Scientific reveals presentations at conference

Boston Scientific has announced key data will be presented at next week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA). For example,...

Analysis of LAA closure devices reveals post-approval spike in safety events

  A retrospective study conducting a safety assessment and comparison between two percutaneous devices commonly used for left atrial appendage (LAA) closure in the US­...

Europace 2017: Thrombus formation on left atrial appendage occlusion devices strongly...

A French multicentre analysis of left atrial appendage (LAA) occlusion for stroke prevention in atrial fibrillation patients has found a 5.3% rate of thrombus...

HRS 2017: Watchman prevents stroke even in high-risk patients: One-year follow-up...

Left atrial appendage closure with the Watchman device (Boston Scientific) is safe and effective at stroke prevention, with a high implant and sealing success,...

Boston Scientific announces scheduled presentations at Heart Rhythm Society 2017

Boston Scientific has announced the schedule of key data presentations, including two late-breaking clinical trials that will be featured at the Heart Rhythm Society’s...

No significant differences between Watchman and Amplatzer in first comparison

Results from the first study to compare outcomes of two left atrial appendage closure devices—Watchman (Boston Scientific) and Amplatzer (St Jude Medical)—indicate that there...

Educational supplement: LAA closure for stroke prophylaxis in atrial fibrillation

This educational supplement is only for readers in countries outside France, Japan and the USA In this educational supplement, sponsored by Boston Scientific, Cardiac Rhythm News explores left...